Published in final edited form as:

J Pediatr. 2014 March ; 164(3): 607–12.e1-7. doi:10.1016/j.jpeds.2013.10.091.

Urine Protein Biomarkers for the Diagnosis and Prognosis of Necrotizing Enterocolitis in Infants

Karl G. Sylvester, MD^{1,2}, Xuefeng B. Ling, PhD², Gigi Yuen-Gee Liu, MD^{2,3}, Zachary J. Kastenberg, MD^{1,2}, Jun Ji, MS, MD², Zhongkai Hu, BS², Shuaibin Wu, PhD², Sihua Peng, PhD², Fizan Abdullah, MD, PhD³, Mary L. Brandt, MD⁴, Richard A. Ehrenkranz, MD⁵, Mary Catherine Harris, MD⁶, Timothy C. Lee, MD⁴, B. Joyce Simpson, RN, MPH⁵, Corinna Bowers, CAP⁷, and R. Lawrence Moss, MD⁷

¹Division of Pediatric Surgery, Lucile Packard Children's Hospital, Palo Alto, CA

²Department of Surgery, Stanford University School of Medicine, Baltimore, MD

³Pediatric Surgery, Department of Surgery, Johns Hopkins University, Baltimore, MD

⁴Pediatric Surgery, Department of Surgery, Texas Children's Hospital, Houston, TX

⁵Department of Pediatrics, Division of Neonatology, Yale University School of Medicine, New Haven, CT

⁶Department of Pediatrics, Division of Neonatology, Children's Hospital of Philadelphia, Philadelphia, PA

⁷Pediatric Surgery, Department of Surgery, Nationwide Children's Hospital, Columbus, OH

Abstract

Objectives—To test the hypothesis that an exploratory proteomics analysis of urine proteins with subsequent development of validated urine biomarker panels would produce molecular classifiers for both the diagnosis and prognosis of infants with necrotizing enterocolitis (NEC).

Study design—Urine samples were collected from 119 premature infants (85 NEC, 17 sepsis, 17 control) at the time of initial clinical concern for disease. The urine from 59 infants was used for candidate biomarker discovery by liquid chromatography/mass spectrometry. The remaining 60 samples were subject to enzyme-linked immunosorbent assay for quantitative biomarker validation.

Results—A panel of 7 biomarkers (alpha-2-macroglobulin-like protein 1, cluster of differentiation protein 14, cystatin 3, fibrinogen alpha chain, pigment epithelium-derived factor, retinol binding protein 4, and vasolin) was identified by liquid chromatography/mass spectrometry and subsequently validated by enzyme-linked immunosorbent assay. These proteins were consistently found to be either up- or down-regulated depending on the presence, absence, or severity of disease. Biomarker panel validation resulted in a receiver-operator characteristic area

Copyright © 2014 Mosby Inc.

Reprint requests: Karl G. Sylvester, MD, Stanford Department of Surgery, Stanford University Medical Center, Lucile Packard Children's Hospital, 777 Welch Road, Suite J, Palo Alto, CA 94305. sylvester@stanford.edu.

The authors declare no conflicts of interest.

under the curve of 98.2% for NEC vs sepsis and an area under the curve of 98.4% for medical NEC vs surgical NEC.

Conclusions—We identified 7 urine proteins capable of providing highly accurate diagnostic and prognostic information for infants with suspected NEC. This work represents a novel approach to improving the efficiency with which we diagnose early NEC and identify those at risk for developing severe, or surgical, disease.

The underlying etiology of necrotizing enterocolitis (NEC) remains poorly understood but is thought to be multifactorial, involving factors inherent to the premature neonate and its environment. Specific features believed to be involved in the development of NEC include an underdeveloped gastrointestinal mucosal barrier, immature innate and humoral immunity, uncoordinated intestinal peristalsis, and pathogenic bacterial overgrowth.¹ Despite many advances in neonatal intensive care, NEC continues to be a major source of morbidity and mortality in preterm infants. It is diagnosed in 1%–5% of all patients in the neonatal intensive care unit, with an incidence of up to 15% reported in infants weighing less than 1500 g.^{2,3}

NEC occurs across a spectrum of severity from a mild form that resolves with antibiotics and cessation of feedings (medical NEC) to a progressive form that leads to intestinal perforation, peritonitis, and potentially death (surgical NEC).⁴ Approximately 20%–40% of all infants diagnosed with NEC eventually require surgery.⁵ Although Bell's classification scheme, first introduced in 1978,⁶ is useful in guiding initial treatment decisions, it does not serve as a prognostic instrument of disease progression.

Many previous attempts have been made to identify biologic markers for the early detection of NEC. Breath hydrogen levels, genomic analyses, targeted inflammatory marker detection, and fecal microbiota profiling have all shown initial promise as predictors of high-risk populations but have achieved limited clinical success for a variety of reasons.^{7–15} In the current study, we used an unbiased exploratory proteomics approach to define a urine protein biomarker panel with the ability to enable both timely diagnosis and accurate prognosis for infants with presumed NEC.

Methods

This was a multi-institutional, multiyear study with prospective data collection performed from May 1, 2007, to August 1, 2012, by trained personnel at each participating institution. Patient contributions by institution included: Yale-New Haven Children's Hospital (n = 42), Johns Hopkins Children's Center (n = 27), Texas Children's Hospital (n = 25), Lucile Packard Children's Hospital (n = 18), and Children's Hospital of Philadelphia (n = 7). Informed consent was obtained from the parents of all enrolled subjects. This study was approved by the human subjects' protection program at each participating institution.

All urine samples were collected at the time of initial clinical concern for disease (NEC or sepsis), a point at which definitive diagnosis was not able to be determined on clinical grounds alone. Patients with a previous diagnosis of NEC or sepsis, a history of previous abdominal surgery, or a known congenital anomaly of the gastrointestinal tract or abdominal

wall were excluded from the study. Patient inclusion was ultimately confirmed by the presence of signs specific for NEC by Bell's criteria (pneumatosis intestinalis) or, for the sepsis group, by either positive blood cultures or a clinical syndrome associated with a high probability of infection. Control subjects were identified as premature infants in the neonatal intensive care unit without known or suspected inflammatory disease.

The study was conducted in 2 phases. The "discovery phase" included urine proteomics analysis by nontargeted, liquid chromatography/mass spectrometry (LCMS) with case and control subjects (n = 45 NEC, n = 12 sepsis, n = 2, controls).^{16,17} To verify the LCMS spectral counts in a proof-of-principle experiment, the cluster of differentiation protein 14 (CD14) LCMS analyte results were compared with CD14 western blot analysis. For the western blot analysis, CD14 MaxPab mouse polyclonal antibody (B01; Abnova, Taipei City, Taiwan) was used as the primary antibody and a fluorescent-labeled secondary antibody was subsequently applied. Gel band intensities were quantified using GelAnalyzer software (<http://www.gelanalyzer.com>).

The "validation phase" consisted of the analysis of a second, naïve patient cohort (n = 40 NEC, n = 5 sepsis, n = 15 healthy controls) for which enzyme-linked immunosorbent assay (ELISA) technology was used to quantify the previously identified urine protein biomarker candidates. All ELISAs were performed according to vendor instructions for the measurement of selected biomarkers in the urine using commercially available kits (Abcam, Cambridge, Massachusetts; Biolegend Inc., San Diego, California; Ebioscience Inc., San Diego, CA; Fisher Scientific, Rockford, Illinois; and Usen Life Science Inc., Wuhan, China). The protein analytes' urine abundance was reported as a normalized ratio of the ELISA-derived concentration to urinary creatinine concentration to correct for urine biological variations.

Statistical Analyses

Patient demographic data were analyzed using the Epidemiological calculator (R epicalc package; <http://cran.r-project.org/web/packages/epicalc/index.html>). Student *t* test was performed to calculate *P* values for continuous variables, and Fisher exact test was used for comparative analysis of categorical variables. Hypothesis testing to detect statistical differences in discovered biomarkers was performed using a Student *t* test (2-tailed) and Mann-Whitney *U* test (2-tailed), along with local false discovery rate¹⁷ methods to correct for multiple hypothesis testing issues.

We then performed biomarker feature selection and panel optimization with the aim to develop a multiplexed antibody-based assay for both the diagnosis and prognosis of NEC. This was accomplished using a genetic algorithm (R genalg package; <http://cran.r-project.org/web/packages/genalg/index.html>) to construct biomarker panels from the validated urine protein biomarkers. Using the validation ELISA data, we identified the optimal biomarker panels by testing all possible combinations of the validated urine protein biomarkers while balancing the need for small panel size, accuracy of classification, goodness of class separation (NEC vs sepsis, medical NEC vs surgical NEC, NEC vs control, and sepsis vs control), and sufficient sensitivity and specificity.

The predictive performance of each biomarker panel analysis was evaluated by receiver-operator characteristic (ROC) curve analysis by plotting the sensitivity vs 1-specificity.^{18–20} The biomarker panel score was defined as the ratio between the geometric means of the respective up- and down-regulated protein biomarkers. To define the performance of the biomarker panels we chose the coordinates on the ROC curve that represented the “cut-off” point with the best sensitivity and specificity as previously described.¹⁹

Results

The only patient characteristic with a statistically significance difference between groups in the discovery cohort was race, with a greater percentage of black infants in the NEC group compared with the sepsis and control groups (Table I). The characteristics with statistically significance differences between groups in the biomarker validation cohort were gestational age and birth weight, with infants in the control group tending to have younger gestational ages and lower birth weights than those in the NEC and sepsis groups. The time between initial clinical concern (ie, the time of urine sample collection) and confirmed medical NEC, defined as the presence of pneumatosis, was median 32 hours (IQR 9.5–66.5). The time between initial clinical concern and confirmation of surgical NEC, defined as the time of laparotomy, peritoneal drain, or death from complication of NEC, was median 48 hours (IQR 12–171.5).

Biomarker discovery (LCMS)

LCMS analysis of urine from the 59 infants in the biomarker discovery cohort revealed 13 candidate proteins with potentially relevant biologic roles: alpha-2-macroglobulin-like protein 1 (A2ML1), apolipoprotein CIII, complement component protein 3, caspase protein 8, CD14, cystatin 3 (CST3), fibrinogen alpha chain (FGA), kininogen protein 1, lectin manose-binding protein 2, pigment epithelium-derived factor (PEDF), Pmp-like secreted protein 2, retinol binding protein 4 (RET4), and vasolin (VASN).

As a verification of the LCMS discovery approach, the differential presence of CD14, a pattern recognition receptor, was confirmed by Western blot analysis comparing medical NEC, surgical NEC, and sepsis urine samples (Figure 1; available at www.jpeds.com). Western blot revealed the alpha-form and beta-form of soluble CD14, both of which are known to be up-regulated in the plasma of adults experiencing proinflammatory conditions.²¹ LCMS spectral counts were then plotted against CD14 Western blot band intensity revealing a correlation coefficient of 0.86 ($P < .001$; Figure 2; available at www.jpeds.com) with the more severe pathology (surgical NEC) having greater levels of CD14 expression by both analytical methods.

Biomarker Validation (ELISA)

The urine samples from the 60 infants in the validation cohort were used for ELISA-based validation of the 13 candidate biomarkers. Seven of the 13 LCMS candidate biomarkers were quantitatively validated (2-tailed Mann-Whitney U tests, $P < .05$; Tables II and III; Table III, available at www.jpeds.com) and consistently shared the same trend of up- or down- regulation between case and control samples when comparing discovery LCMS and

validation ELISA results. In addition, individual ROC curves were plotted for each validated analyte and the point of intersection for optimal sensitivity and specificity was computed, demarcated, and reported (Figure 3 and Table IV; available at www.jpeds.com).

The genetic algorithm panel construction process led to the design of four distinct biomarker panels with complete separation between NEC vs sepsis, medical NEC vs surgical NEC, NEC vs control, and sepsis vs control (Table V and Figure 4). These biomarker panels are nonredundant, indicative of their noninclusive relationships.

Importantly, each biomarker panel was able to differentiate between the groups with sensitivities ranging from 0.89 to 0.96 and specificity ranging from 0.80 to 0.90 (Figure 4). Not surprisingly, the panels assessing infants with diagnoses more closely related in severity of inflammation had lower sensitivity (NEC vs sepsis, 0.89; and medical NEC vs surgical NEC, 0.89) compared with the panels including the controls (NEC vs control, 0.96; and sepsis vs control, 0.90).

Discussion

Considerable effort has been directed toward the identification of biomarkers of NEC given the inability to predict the ultimate course of disease based on clinical variables alone.²² Exploratory proteomics enables the unbiased identification of candidate biomarkers before clinical manifestation of disease. Urine biomarker panels, specifically, hold the potential to provide low-risk, low-cost facilitation of clinical decision-making. The urine protein biomarkers described in the current study enabled the accurate diagnosis of NEC amongst a population of infants with NEC, infants with non-NEC sepsis, and noninfected premature infants. In addition, these biomarkers showed potential prognostic value, as they were also able to accurately differentiate between infants with medical NEC and those with surgical NEC.

Many previous studies have investigated the diagnostic capabilities of targeted biomarkers for NEC. Epidermal growth factor,^{23,24} interalpha inhibitor proteins,^{25–28} intestinal fatty acid-binding protein,^{29–33} and fecal calprotectin,³⁴ have all been identified as potential biomarkers of NEC in human infants. In addition, a number of interleukins (ILs) and other inflammatory factors are either up-regulated (IL 1, 6, 8, and 12, tumor necrosis factor-alpha, interferon, and platelet-activating factor), down-regulated, or temporally correlated with the severity of disease (IL 4, 10, and 11) in infants with NEC or other inflammatory conditions of infancy.^{35–42} Despite promising results, no single biomarker has proven to be useful as a stand-alone diagnostic test in clinical practice. In contrast, the current study made use of a nontargeted, exploratory approach to identify several candidate biomarkers. The biomarker panels were subsequently validated on a naïve population with relatively strong diagnostic (NEC vs sepsis; mean area under the curve 98.2%, sensitivity 0.89, specificity 0.80) and prognostic (medical NEC vs surgical NEC; mean area under the curve 98.4%, sensitivity 0.89, specificity 0.90) capabilities.

Importantly, many of these have potential physiologic bases for their association with NEC. Alpha-2macroglobulin (which shares significant homology with A2ML1) and FGA are both

components of the coagulation cascade, a potentially significant finding given that coagulation necrosis is a common pathologic finding in NEC resection specimens. VASN is an inhibitor of transforming growth factor-beta, and is down-regulated after vascular injury,⁴³ a finding consistent with lower urine levels of VASN in the surgical NEC cohort. The pattern recognition receptor CD14 is a regulator of the innate immune system that plays a role in the response to bacterial lipopolysaccharide, potentially explaining its elevation in the surgical NEC cohort, a patient group with more extensive bowel injury and thus bacterial invasion. CST3 has been described as a biomarker for acute kidney injury,⁴⁴ likely explaining its presence in greater levels in the urine as systemic disease progresses. Although these associations are intriguing, further investigation is needed to identify causal relationships and to provide further biologic insight.

This study demonstrates the utility of unbiased biomarker discovery platforms in which proteins with correlated and potentially causal relationships to the pathophysiology of disease can be identified. The clinical potential of the described biomarker panel was highlighted by the validation on a naïve population, even though the inclusion of the sepsis group in addition to the noninfected control group confirmed that the identified biomarkers were not simply markers of a generic proinflammatory state.

A significant limitation of our approach, indeed a characteristic inherent to any proteomics-based study, was the absence of a clear pathophysiologic link between the identified biomarkers and the pathology in question. As previously mentioned, many of the biomarkers identified and validated in this study are related to known coagulation, inflammatory, or immunologic cascades. Although not confirming causal significance, this is an interesting finding that requires additional study.

Another important limitation of this pilot study is the relatively small cohort size illustrating the need for further prospective validation and longitudinal testing. Furthermore, there were noted differences in, and thus possible confounding of our results by, gestational age and birth weight between the study groups in the biomarker validation cohort. Future studies will be needed to address impact of these factors on biomarker validity. Despite such limitations, the quantitative differences in urine biomarker levels between multiple study groups validated on a naïve population suggest potential future clinical utility.

The use of an unbiased exploratory proteomics approach to identify urine biomarkers for NEC led to the development of a panel of validated proteins that demonstrate promise as a clinically useful instrument. The incorporation of additional targeted biomarkers along with patient-specific clinical information will likely strengthen the utility of the described biomarkers and is an important area of ongoing investigation. With continued refinement, it appears likely that a biomarker-based instrument will lead to more efficient diagnosis, more timely intervention, and improved outcomes for infants affected by one of the most common and debilitating diseases of prematurity.

Acknowledgments

Funded by the Lucile Packard Foundation for Children's Health, the Food and Drug Administration (1U01FD004194-01) [to K.S.], Ikaria Inc, the INSPIRE Center at Nationwide Children's Hospital, the Jack and

Marion Euphrat Fellowship in Pediatric Translational Medicine, and Stanford University (CTSA UL1 RR025744 to Z.K.).

Glossary

A2ML1	Alpha-2-macroglobulin-like protein 1
CD14	Cluster of differentiation protein 14
CST3	Cystatin 3
ELISA	Enzyme-linked immunosorbent assay
FGA	Fibrinogen alpha chain
IL	interleukin
LCMS	Liquid chromatography/mass spectrometry
NEC	Necrotizing enterocolitis
PEDF	Pigment epithelium-derived factor
RET4	Retinol binding protein 4
ROC	Receiver-operator characteristic
VASN	Vasolin

References

1. Lin PW, Nasr TR, Stoll BJ. Necrotizing enterocolitis: recent scientific advances in pathophysiology and prevention. *Semin Perinatol.* 2008; 32:70–82. [PubMed: 18346530]
2. Kamitsuka MD, Horton MK, Williams MA. The incidence of necrotizing enterocolitis after introducing standardized feeding schedules for infants between 1250 and 2500 grams and less than 35 weeks of gestation. *Pediatrics.* 2000; 105:379–384. [PubMed: 10654959]
3. Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ, et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 Through December 1996. NICHD Neonatal Research Network. *Pediatrics.* 2001; 107:e1–e8. [PubMed: 11134465]
4. Hintz SRKD, Stoll BJ, Vohr BR, Fanaroff AA, Donovan EF, et al. Neurodevelopmental and growth outcomes of extremely low birth weight infants after necrotizing enterocolitis. *Pediatrics.* 2005; 117:696–703. [PubMed: 15741374]
5. Henry MC, Moss RL. Neonatal necrotizing enterocolitis. *Semin Pediatr Surg.* 2008; 17:98–109. [PubMed: 18395659]
6. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. *Ann Surg.* 1978; 187:1–7. [PubMed: 413500]
7. Young C, Sharma R, Handfield M, Mai V, Neu J. Biomarkers for infants at risk for necrotizing enterocolitis: clues to prevention? *Pediatr Res.* 2009; 65:91R–97R.
8. Cheu HW, Brown DR, Rowe MI. Breath hydrogen excretion as a screening test for the early diagnosis of necrotizing enterocolitis. *Am J Dis Child.* 1989; 143:156–159. [PubMed: 2492749]
9. Moonen RM, Paulussen AD, Souren NY, Kessels AG, Rubio-Gozalbo ME, Villamor E. Carbamoyl phosphate synthetase polymorphisms as a risk factor for necrotizing enterocolitis. *Pediatr Res.* 2007; 62:188–190. [PubMed: 17597649]
10. Treszl A, Heninger E, Kalman A, Schuler A, Tulassay T, Vasarhelyi B. Lower prevalence of IL-4 receptor alpha-chain gene G variant in very-low-birth-weight infants with necrotizing enterocolitis. *J Pediatr Surg.* 2003; 38:1374–1378. [PubMed: 14523823]

11. Hoy C, Millar MR, MacKay P, Godwin PG, Langdale V, Levene MI. Quantitative changes in faecal microflora preceding necrotising enterocolitis in premature neonates. *Arch Dis Child*. 1990; 65:1057–1059. [PubMed: 2122814]
12. Peter CS, Feuerhahn M, Bohnhorst B, Schlaud M, Ziesing S, von der Hardt H, et al. Necrotising enterocolitis: is there a relationship to specific pathogens? *Eur J Pediatr*. 1999; 158:67–70. [PubMed: 9950312]
13. Sharma R, Tepas JJ 3rd, Hudak ML, Mollitt DL, Wludyka PS, Teng RJ, et al. Neonatal gut barrier and multiple organ failure: role of endotoxin and proinflammatory cytokines in sepsis and necrotizing enterocolitis. *J Pediatr Surg*. 2007; 42:454–461. [PubMed: 17336180]
14. Pourcyrous M, Korones SB, Yang W, Boulden TF, Bada HS. C-reactive protein in the diagnosis, management, and prognosis of neonatal necrotizing enterocolitis. *Pediatrics*. 2005; 116:1064–1069. [PubMed: 16263990]
15. Carroll D, Corfield A, Spicer R, Cairns P. Faecal calprotectin concentrations and diagnosis of necrotising enterocolitis. *Lancet*. 2003; 361:310–311. [PubMed: 12559868]
16. Ling XB, Sylvester KG. Proteomics and biomarkers in neonatology. *Neo-Reviews*. 2011:585–591.
17. Ling XB, Mellins ED, Sylvester KG, Cohen HJ. Urine peptidomics for clinical biomarker discovery. *Adv Clin Chem*. 2010; 51:181–213. [PubMed: 20857622]
18. Efron B, Tibshirani R, Storey J, Tusher V. Empirical bayes analysis of microarray experiment. *J Am Stat Assoc*. 2001; 96:1151–1160.
19. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. *Clin Chem*. 1993; 39:561–577. [PubMed: 8472349]
20. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCr: visualizing classifier performance in R. *Bioinformatics*. 2005; 21:3940–3941. [PubMed: 16096348]
21. Fingerle-Rowson G, Auers J, Kreuzer E, Labeta M, Schmidt B, Samtleben W, et al. Down-regulation of surface monocyte lipopolysaccharide-receptor CD14 in patients on cardiopulmonary bypass undergoing aorta-coronary bypass operation. *J Thorac Cardiovasc Surg*. 1998; 115:1172–1178. [PubMed: 9605088]
22. Moss RL, Kalish LA, Duggan C, Johnston P, Brandt ML, Dunn JC, et al. Clinical parameters do not adequately predict outcome in necrotizing enterocolitis: a multi-institutional study. *J Perinatol*. 2008; 28:665–674. [PubMed: 18784730]
23. Helmuth MA, Shin CE, Fox JW, Erwin CR, Warner BW. Epidermal growth factor in saliva and serum of infants with necrotising enterocolitis. *Lancet*. 1998; 351:266–267. [PubMed: 9457103]
24. Shin CE, Falcone RA Jr, Stuart L, Erwin CR, Warner BW. Diminished epidermal growth factor levels in infants with necrotizing enterocolitis. *J Pediatr Surg*. 2000; 35:173–176. discussion 7. [PubMed: 10693661]
25. Lim YP, Bendelja K, Opal SM, Siryaporn E, Hixson DC, Palardy JE. Correlation between mortality and the levels of inter-alpha inhibitors in the plasma of patients with severe sepsis. *J Infect Dis*. 2003; 188:919–926. [PubMed: 12964125]
26. Chaaban H, Singh K, Huang J, Siryaporn E, Lim YP, Padbury JF. The role of inter-alpha inhibitor proteins in the diagnosis of neonatal sepsis. *J Pediatr*. 2009; 154:620–622. e1. [PubMed: 19324226]
27. Baek YW, Brokat S, Padbury JF, Pinar H, Hixson DC, Lim YP. Interalpha inhibitor proteins in infants and decreased levels in neonatal sepsis. *J Pediatr*. 2003; 143:11–15. [PubMed: 12915817]
28. Chaaban H, Shin M, Sarya E, Lim YP, Caplan M, Padbury JF. Inter-alpha inhibitor protein level in neonates predicts necrotizing enterocolitis. *J Pediatr*. 2010; 157:757–761. [PubMed: 20955849]
29. Lieberman JM, Sacchettini J, Marks C, Marks WH. Human intestinal fatty acid binding protein: report of an assay with studies in normal volunteers and intestinal ischemia. *Surgery*. 1997; 121:335–342. [PubMed: 9068676]
30. Edelson MB, Sonnino RE, Bagwell CE, Lieberman JM, Marks WH, Rozycki HJ. Plasma intestinal fatty acid binding protein in neonates with necrotizing enterocolitis: a pilot study. *J Pediatr Surg*. 1999; 34:1453–1457. [PubMed: 10549746]
31. Guthmann F, Borchers T, Wolfrum C, Wustrack T, Bartholomaeus S, Spener F. Plasma concentration of intestinal-and liver-FABP in neonates suffering from necrotizing enterocolitis and in healthy preterm neonates. *Mol Cell Biochem*. 2002; 239:227–234. [PubMed: 12479590]

32. Derikx JP, Evennett NJ, Degraeuwe PL, Mulder TL, van Bijnen AA, van Heurn LW, et al. Urine based detection of intestinal mucosal cell damage in neonates with suspected necrotising enterocolitis. *Gut*. 2007; 56:1473–1475. [PubMed: 17872576]
33. Evennett NJ, Hall NJ, Pierro A, Eaton S. Urinary intestinal fatty acid-binding protein concentration predicts extent of disease in necrotizing enterocolitis. *J Pediatr Surg*. 2010; 45:735–740. [PubMed: 20385280]
34. Reisinger KW, Van der Zee DC, Brouwers HA, Kramer BW, van Heurn LW, Buurman WA, et al. Noninvasive measurement of fecal calprotectin and serum amyloid A combined with intestinal fatty acid-binding protein in necrotizing enterocolitis. *J Pediatr Surg*. 2012; 47:1640–1645. [PubMed: 22974599]
35. Martin CR, Walker WA. Intestinal immune defences and the inflammatory response in necrotising enterocolitis. *Semin Fetal Neonatal Med*. 2006; 11:369–377. [PubMed: 16690363]
36. Edelson MB, Bagwell CE, Rozycki HJ. Circulating pro- and counterinflammatory cytokine levels and severity in necrotizing enterocolitis. *Pediatrics*. 1999; 103:766–771. [PubMed: 10103300]
37. Caplan MS, Sun XM, Hseuh W, Hageman JR. Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis. *J Pediatr*. 1990; 116:960–964. [PubMed: 2348301]
38. Viscardi RM, Lyon NH, Sun CC, Hebel JR, Hasday JD. Inflammatory cytokine mRNAs in surgical specimens of necrotizing enterocolitis and normal newborn intestine. *Pediatr Pathol Lab Med*. 1997; 17:547–559. [PubMed: 9211547]
39. Nadler EP, Stanford A, Zhang XR, Schall LC, Alber SM, Watkins SC, et al. Intestinal cytokine gene expression in infants with acute necrotizing enterocolitis: interleukin-11 mRNA expression inversely correlates with extent of disease. *J Pediatr Surg*. 2001; 36:1122–1129. [PubMed: 11479840]
40. Halpern MD, Holubec H, Dominguez JA, Williams CS, Meza YG, McWilliam DL, et al. Up-regulation of IL-18 and IL-12 in the ileum of neonatal rats with necrotizing enterocolitis. *Pediatr Res*. 2002; 51:733–739. [PubMed: 12032269]
41. Treszl A, Tulassay T, Vasarhelyi B. Genetic basis for necrotizing enterocolitis–risk factors and their relations to genetic polymorphisms. *Front Biosci*. 2006; 11:570–580. [PubMed: 16146753]
42. Jones CA, Cayabyab RG, Kwong KY, Stotts C, Wong B, Hamdan H, et al. Undetectable interleukin (IL)-10 and persistent IL-8 expression early in hyaline membrane disease: a possible developmental basis for the predisposition to chronic lung inflammation in preterm newborns. *Pediatr Res*. 1996; 39:966–975. [PubMed: 8725256]
43. Ikeda Y, Imai Y, Kumagai H, Nosaka T, Morikawa Y, Hisaoka T, et al. Vascularin, a transforming growth factor beta-binding protein expressed in vascular smooth muscle cells, modulates the arterial response to injury in vivo. *Proc Natl Acad Sci U S A*. 2004; 101:10732–10737. [PubMed: 15247411]
44. Urbschat A, Obermuller N, Haferkamp A. Biomarkers of kidney injury. *Biomarkers*. 2011; 16(Suppl 1):S22–S30. [PubMed: 21707441]

Figure 1. Western blot analysis of urine CD14. *M*, medical, *S*, surgical; *sCD-14*, soluble CD14.

Figure 2.

Correlation of CD14 LCMS spectral counts and CD14 Western blot gel band intensity for infants in the sepsis, medical NEC, and surgical NEC groups. *Coef*, coefficient.

B

C

Figure 3.

Single analyte biomarker's performances in discriminating **A**, medical and surgical NEC; **B**, NEC and control; **C**, NEC and sepsis; and **D**, sepsis and control classes were analyzed by ROC analysis. The Y-axis is the sensitivity and X-axis is the $1 - \text{specificity}$. The *red* dot represents the point of optimized sensitivity and specificity and is listed under each ROC plot. A total of 500 testing data sets were generated by bootstrapping methods from the ELISA data and were used to derive estimates of SE and CIs for the ROC analyses. The plotted ROC curve represents the vertical average of the 500 bootstrapping runs, and the box and whisker plots show the vertical spread around the average.

Figure 4.

Biomarker panel ROC curves. The *black dots* represent “cut-off” points along the ROC curves, indicating the best sensitivity and specificity coordinates. **A**, NEC vs sepsis consists of 3 proteins: CST3, PEDF, and RET4. **B**, Medical NEC vs surgical NEC consists of 6 proteins: A2ML1, CD14, CST3, PEDF, RET4, and VASN. **C**, NEC vs control consists of 3 proteins: CST3, PEDF, and RET4. **D**, Sepsis vs control consists of 4 proteins: A2ML1, CST3, FGA, and VASN. *Significant and highly significant. AUC, area under the curve.

Table 1

Patient characteristics

	NEC				
	Discovery cohort (n = 59)	Medical NEC (n = 29)	Surgical NEC (n = 16)	Total NEC (n = 45)	Sepsis (n = 12)
No. Obs.	n = 26	n = 14	n = 40	n = 2	n = 2
Sex					
Female	12 (46.2%)	7 (50.0%)	19 (47.5%)	7 (58.3%)	2 (100.0%)
Male	14 (53.8%)	7 (50.0%)	21 (52.5%)	5 (41.7%)	0 (0.0%)
Race*					
Asian	1 (3.4%)	0 (0.0%)	1 (5.0%)	1 (8.3%)	2 (100.0%)
Black	8 (27.6%)	5 (31.2%)	13 (28.9%)	0 (0.0%)	0 (0.0%)
White	16 (55.2%)	6 (37.5%)	22 (48.9%)	11 (91.7%)	0 (0.0%)
Unknown	4 (13.8%)	5 (31.5%)	9 (20.0%)	0 (0.0%)	0 (0.0%)
Gestational age, wk					
Median (IQR)	28.5 (27–32)	28.5 (25–31.8)	28.5 (27–32)	28 (26.5–32.5)	30.5 (28.2–32.8)
Birth weight, g					
Median (IQR)	1095 (938–1952)	970 (740.5–1771.2)	1070 (850–1947.8)	1047.5 (840–1927.5)	1840 (1350–2330)
Birth length, cm					
Median (IQR)	36 (33–42)	34.5 (33–43.2)	35.75 (33–43.2)	37 (32–43)	41 (34–48)
Birth head circumference, cm					
Median (IQR)	26 (24.5–31)	24.5 (23.5–27.9)	26 (23.5–30.2)	24.5 (24–28.8)	28.5 (26.2–30.8)
NEC					
	NEC				
	Validation cohort (n = 59)	Medical NEC (n = 30)	Surgical NEC (n = 10)	Total NEC (n = 40)	Sepsis (n = 5)
Sex					
Female	16 (53.3%)	2 (20.0%)	18 (45.0%)	3 (60.0%)	6 (40.0%)
Male	14 (46.7%)	8 (80.0%)	22 (55.0%)	2 (40.0%)	9 (60.0%)
Race					
Asian	2 (6.7%)	0 (0.0%)	2 (5.0%)	0 (0.0%)	0 (0.0%)
Black	13 (43.3%)	3 (30.0%)	16 (40.0%)	3 (60.0%)	7 (46.7%)

White	13 (43.3%)	6 (60.0%)	19 (47.5%)	1 (20.0%)	7 (46.7%)
Unknown	2 (6.7%)	1 (10.0%)	3 (7.5%)	1 (20.0%)	1 (6.7%)
Gestational age, wk [*]					
Median (IQR)	30 (27–33)	27.5 (25–32)	29.5 (27–32.5)	28 (26–31.5)	26 (25–27.5)
Birth weight, g [*]					
Median (IQR)	1265 (935–1873.5)	1285 (796.5–1912.5)	1265 (907–1943.8)	950 (900–961)	730 (632.5–937.5)
Birth length, cm					
Median (IQR)	37 (34.1–41.8)	34.5 (32–42.8)	37 (32.9–42.2)	34 (31–36)	33.8 (32–36)
Birth head circumference, cm					
Median (IQR)	27.2 (25–30.5)	24.4 (23–28)	27 (23.9–30.1)	24.2 (23.4–24.6)	23 (21.8–26)

Obs, observations.

^{*} $P < .05$.

Table IIELISA biomarker validation by Mann-Whitney *U* test

Analyte	Mann-Whitney <i>U</i> test <i>P</i> value			
	NEC M vs NEC S	NEC vs Sepsis	NEC vs control	Sepsis vs control
A2ML1	.02*	.08	$1.40 \times 10^{-4}\dagger$	.50
CD14	.02*	.77	0.12	.35
CST3	0.12	.58	.03*	.35
FGA	.02*	.8	0.06	.16
PEDF	$1.82 \times 10^{-3}\dagger$	.03*	$2.23 \times 10^{-4}\dagger$	.67
RET4	6.89×10^{-3}	.64	0.11	.50
VASN	0.09	.80	.02*	.12

NEC M, medical NEC; NEC S, surgical NEC.

Table III

Validated biomarker levels by pathologic group

NEC													
M			S			M + S			Sepsis			Control	
Analyte	Unit	Median (IRQ)	Mean (SD)	Median (IRQ)	Mean (SD)	Median (IRQ)	Mean (SD)	Median (IRQ)	Mean (SD)	Median (IRQ)	Mean (SD)	Median (IRQ)	Mean (SD)
A2ML1	Analyte/Cr, ng/mg	61.55 (14.12–166.37)	174.03 (346.64)	3.79 (1.40–9.51)	22.25 (47.81)	28.28 (3.79–130.13)	138.61 (309.67)	3.32 (1.55–9.06)	5.30 (6.37)	1.68 (0.96–3.36)	2.71 (3.03)		
CD14	Analyte/Cr, ng/mg	174.40 (84.74–524.22)	451.76 (726.18)	895.49 (231.43–2601.20)	2740.24 (5004.98)	212.66 (110.28–679.12)	979.87 (2574.92)	186.53 (100.67–655.39)	367.62 (361.03)	89.44 (39.14–574.68)	295.63 (375.31)		
CST4	Analyte/Cr, ng/mg	43.70 (21.30–225.23)	215.50 (416.28)	227.20 (120.54–605.62)	355.27 (352.39)	87.30 (23.16–239.16)	248.39 (401.55)	94.22 (59.22–111.59)	81.14 (52.93)	31.14 (12.89–86.68)	51.12 (47.37)		
FGA	Analyte/Cr, ng/mg	15.78 (9.26–33.81)	74.18 (143.97)	69.50 (46.25–237.97)	408.39 (862.69)	21.57 (9.95–97.57)	157.73 (456.77)	29.06 (15.51–175.91)	95.71 (149.33)	15.52 (4.23–23.63)	22.67 (35.07)		
PEDF	Analyte/Cr, ng/mg	4.40 (1.57–25.31)	66.05 (228.22)	122.04 (7.14–257.70)	225.45 (309.84)	8.60 (2.79–105.75)	115.86 (262.27)	111.66 (100.56–134.47)	212.40 (225.50)	217.34 (57.49–491.52)	378.60 (411.31)		
RET4	Analyte/Cr, ng/mg	417.89 (188.59–655.45)	642.35 (846.82)	1122 (898.48–2083.34)	5549.31 (12 299.56)	512.72 (197.95–1115.57)	1796.93 (6090.69)	454.38 (337.35–655.21)	463.24 (220.19)	298.60 (115.29–692.03)	406.36 (357.47)		
VASN	Analyte/Cr, ng/mg	23.93 (9.78–129.94)	97.17 (163.15)	9.8 (6.32–21.43)	17.04 (18.11)	19.99 (9.04–52.85)	78.68 (146.81)	13.67 (10.70–43.44)	26.40 (24.62)	2.74 (0.54–22.83)	11.04 (12.62)		

Cr, creatinine.

Table IV

Individual biomarker intercohort testing characteristics

Analyte	NEC M vs NEC S			NEC vs control			NEC vs sepsis			Sepsis vs control		
	ROC AUC	Sensitivity*	Specificity*	ROC AUC	Sensitivity*	Specificity*	ROC AUC	Sensitivity*	Specificity*	ROC AUC	Sensitivity*	Specificity*
A2ML1	80.40%	0.80	0.70	84.90%	0.76	0.80	77.50%	0.56	0.80	0.78	0.56	0.80
CD14	77.50%	0.60	0.80	65.10%	0.64	0.60	55.90%	0.56	0.50	0.56	0.56	0.50
CST4	68.40%	0.73	0.60	70.20%	0.49	0.80	58.20%	0.4	0.80	0.58	0.40	0.80
FGA	74.40%	0.73	0.70	68.40%	0.52	0.70	56.20%	0.48	0.60	0.56	0.48	0.60
PEDF	83.90%	0.68	0.80	83.40%	0.69	0.80	80.60%	0.68	0.80	0.58	0.60	0.60
RET4	81.00%	0.81	0.70	65.50%	0.47	0.70	58.60%	0.47	0.70	0.62	0.78	0.50
VASN	70.00%	0.59	0.70	73.30%	0.68	0.60	54.50%	0.56	0.50	0.76	0.73	0.60

AUC, area under the curve.

* The optimal sensitivity and specificity point along the ROC curve.

Table V

Biomarker panels for NEC M vs NEC S, NEC vs control, NEC vs sepsis, and sepsis vs control classifications

Analyte	Sample panel score							Sample panel score					
	A2ML1	CD14	CST3	FGA	PEDF	RET4	VASN	Class	Median (IQR)	Mean (SD)	Class	Median (IQR)	Mean (SD)
Clinical usefulness													
NEC M vs NEC S	+↑	+↓	+↓	-	+↓	+↓	+↑	NEC M	2.1 (0.8-2.5)	2.64 (3.60)	NEC S	125.5 (28.9-208.9)	118.9 (105.7)
NEC vs Control	-	-	+↑	-	+↓	+↑	-	NEC	19.4 (9.7-67.9)	161.35 (596.71)	Control	0.4 (0.23-1.1)	0.8 (0.8)
NEC vs Sepsis	-	-	+↑	-	+↓	+↑	-	NEC	19.4 (9.7-67.9)	161.35 (596.71)	Sepsis	1.4 (0.49-1.9)	1.3 (1.1)
Sepsis vs control	+↑	-	+↑	+↑	-	-	+↑	Sepsis	21.2 (20.4-48.1)	38.60 (31.50)	Control	4.3 (2.26-12.8)	10.4 (13.0)

Sample panel score was defined as the ratio of the geometric mean of the up-regulated panel markers' assay results and those of the down-regulated panel markers' assay results.